The XPRIZE Healthspan competition rewards therapies that restore at least 10 years of muscle, cognitive, and immune function to elderly individuals. Late-stage clinical-trial evidence is the prize criterion.
Trellison's role on this track is at the methodology-audit layer, not the therapeutic-development layer. Late-stage clinical trial evidence is exactly where research-integrity verification adds the most value: peer review can fail, replication can fail, and adversarial press can mischaracterize. The CVR Protocol's three-layer evidence package — posterior + convergence diagnostic + conformal coverage — applies cleanly to clinical-trial outcomes once instrumented.
Feedback from visitors, translated into business terminology and listed below. Use the assistant in the corner to add a comment.